GCC Pharma Margins Face 2026 Shift

Q1. Could you start by giving us a brief overview of your professional background, particularly focusing on your expertise in the industry?

I work in pharmaceutical business development and commercial operation & strategy in the GCC, with strong exposure to the KSA & UAE markets in particular. My experience spans marketing & sales management, portfolio evaluation, distributor selection, market-entry planning, pricing logic, and commercial execution across both specialty and broader prescription-driven categories.

Q2. With the 2026 mandates for local production in the UAE and Saudi Arabia, what is the 'true' margin benefit of shifting from an import model to a locally-contract-manufactured one?

The real benefit is usually not a simple gross-margin uplift; it is a strategic mix of regulatory alignment, faster replenishment, lower supply-chain friction, and better tender positioning as both the UAE and KSA continue to push industrial localization. In practice, the net gain depends on scale, tech-transfer complexity, batch economics, and whether the product has enough volume to absorb the local operating structure within GCC.

Q3. As reference biologics worth billions lose exclusivity in 2026, what is the 'Ground-Level' timeline for biosimilar absorption in the GCC hospital sector?

On the ground, biosimilar absorption is rarely immediate; real uptake…